FDA Approves First ctDNA-Guided Adjuvant Immunotherapy for Bladder Cancer, Rewriting the Post-Surgery Treatment Playbook
Atezolizumab becomes the first therapy cleared for use only in patients whose blood tests reveal molecular residual disease after bladder removal surgery.
5 min read5 sources